echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Toeker bioTERN-101 obtained fast-track qualification granted by fda to treat NASH indications

    Toeker bioTERN-101 obtained fast-track qualification granted by fda to treat NASH indications

    • Last Update: 2020-06-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, Terns Pharmaceuticals announced that itsdrug(http://Faniol X receptor (FXR) agonist TERN-101 has been awarded fast Track Track for the treatment of NASH indications by the U.SFood and Drug Administration (
    FDA(http://About TERN-101
    TERN-101 is a powerful non-bile acid-fanol X receptor (FXR) agonist that is currently being developed for the treatment of NASHFXR is a nuclear receptor that is highly expressed in the liver and small intestineBile acid (BA) is a natural ligand of FXR, its binding and activation with FXR is essential for regulating the regulation of the cellular pathways of bile acidsynthesis(http://, lipid metabolism, inflammation and fibrosisRecently disclosed clinicaltrial(http:// results showed that FXR activation significantly improved liver tissue fibrosis in NASH patients compared to placebo, while NASH did not deteriorate, indicating the potential of FXR agonists as new treatments for NAFLD and NASH   In Phase I clinical studies, TERN-101 shows clinical pharmacokinetic properties consistent with daily administration At the
    of the International Conference on Hepatology 2019 in Vienna, the of the International Of Diseases (http:// Tutoson Bio released preclinical research data confirming that TERN-101 reduced liver fat degeneration, inflammation, balloon-like change and fibrosis in NASH preclinical animal models   TERN-101 and TERN-201 (amino-sensitive amine oxidase (SSAO) inhibitors) are currently clinically developed for the treatment of NASH, both of which were originally discovered and developed by Lilly   In 2018, Tutobios and Lilly signed a global exclusive agreement on the development, production and commercialization of TERN-101 and TERN-201 for the treatment of NASH
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.